"We are a clinical development company, which identifies and develops innovative safe and effective therapeutic use of existing drugs in new disease areas. We work through outsourcing activities to competent partners and service providers."
Please klick on the PDF-icon to view newspage or use link.
May 15, 2008
Terguride receives FDA orphan drug designation for the treatment of pulmonary arterial hypertension
